Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RWJ-51204 is a selective adenosine A2A receptor antagonist and a partial agonist of GABA(A) receptor (IC50: 0.2-2 nM). It has neuroprotective and movement-improving effects and can be used in research related to Parkinson's disease.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 350.00 | |
5 mg | In stock | $ 828.00 | |
10 mg | In stock | $ 1,130.00 | |
25 mg | In stock | $ 1,590.00 | |
50 mg | In stock | $ 1,980.00 | |
100 mg | In stock | $ 2,500.00 | |
500 mg | In stock | $ 4,900.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 738.00 |
Description | RWJ-51204 is a selective adenosine A2A receptor antagonist and a partial agonist of GABA(A) receptor (IC50: 0.2-2 nM). It has neuroprotective and movement-improving effects and can be used in research related to Parkinson's disease. |
Targets&IC50 | GABAA:0.2-2 nM(ki) |
In vitro | RWJ-51204 binds to receptors with Ki ranging from 0.2 to 0.6 nM in the cerebral cortex, cerebellum, or medulla-spinal cord.[1] |
In vivo | RWJ-51204 is effective in the conflict test in monkeys (ED50 of approximately 0.5 mg/kg p.o.). RWJ-51204 is orally active in anxiolytic efficacy tests. RWJ-51204 effectively impairs rotarod performance in rats (ED50 = 0.12 mg/kg), and all rats given RWJ-51204 orally at 30 mg/kg exhibit sedation, reduced skeletal muscle tone, and impairment of rotarod performance. [1] |
Molecular Weight | 399.39 |
Formula | C21H19F2N3O3 |
CAS No. | 205701-85-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.99 mg/mL (10 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
RWJ-51204 205701-85-5 Membrane transporter/Ion channel Neuroscience GABA Receptor RWJ51204 RWJ 51204 inhibitor inhibit